BR112014007718A2 - método para preparar hidrocloreto de 1-(4-(4-(3,4-dicloro-2-fluorofenilamino)-7-metoxiquinazolin-6-iloxi)piperidin-1-il)-prop-2-en-1-ona e intermediários usados no mesmo - Google Patents

método para preparar hidrocloreto de 1-(4-(4-(3,4-dicloro-2-fluorofenilamino)-7-metoxiquinazolin-6-iloxi)piperidin-1-il)-prop-2-en-1-ona e intermediários usados no mesmo

Info

Publication number
BR112014007718A2
BR112014007718A2 BR112014007718A BR112014007718A BR112014007718A2 BR 112014007718 A2 BR112014007718 A2 BR 112014007718A2 BR 112014007718 A BR112014007718 A BR 112014007718A BR 112014007718 A BR112014007718 A BR 112014007718A BR 112014007718 A2 BR112014007718 A2 BR 112014007718A2
Authority
BR
Brazil
Prior art keywords
methoxyquinazolin
fluorophenylamino
yloxy
piperidin
prop
Prior art date
Application number
BR112014007718A
Other languages
English (en)
Other versions
BR112014007718B1 (pt
Inventor
Chan Bang Keuk
Ho Moon Young
Kil Chang Young
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48044309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014007718(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Publication of BR112014007718A2 publication Critical patent/BR112014007718A2/pt
Publication of BR112014007718B1 publication Critical patent/BR112014007718B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Abstract

resumo “método para preparar hidrocloreto de 1-(4-(4-(3,4-dicloro-2-fluorofenilamino)-7-metoxiquinazolin-6-iloxi)piperidin-1-il)-prop-2-en-1-ona e intermediários usados no mesmo” a presente invenção se refere a um método aprimorado para preparar hidrocloreto de 1-(4-(4-(3,4-dicloro-2-fluorofenilamino)-7-metoxiquinazolin-6-iloxi)piperidin-1-il)-prop-2-en-1-ona, que seletivamente e eficientemente inibe o desenvolvimento de células de câncer induzido por super expressão de um receptor de fator de desenvolvimento de epiderme (egfr) e evita o desenvolvimento de resistência a fármaco causada por mutação de a tirosina quinase, e intermediários usados no mesmo.
BR112014007718-5A 2011-10-05 2012-10-05 Método para preparar hidrocloreto de 1-(4-(4-(3,4-dicloro-2-fluorofenilamino)-7- metoxiquinazolin-6-iloxi)piperidin-1-il)-prop-2-en-1-ona e intermediários usados no mesmo BR112014007718B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2011-0101422 2011-10-05
KR1020110101422A KR101272613B1 (ko) 2011-10-05 2011-10-05 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체
PCT/KR2012/008077 WO2013051883A2 (en) 2011-10-05 2012-10-05 Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-prop-2-en-1-one hydrochloride and intermediates used therein

Publications (2)

Publication Number Publication Date
BR112014007718A2 true BR112014007718A2 (pt) 2017-04-25
BR112014007718B1 BR112014007718B1 (pt) 2022-02-22

Family

ID=48044309

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014007718-5A BR112014007718B1 (pt) 2011-10-05 2012-10-05 Método para preparar hidrocloreto de 1-(4-(4-(3,4-dicloro-2-fluorofenilamino)-7- metoxiquinazolin-6-iloxi)piperidin-1-il)-prop-2-en-1-ona e intermediários usados no mesmo

Country Status (23)

Country Link
US (1) US8859767B2 (pt)
EP (2) EP3611172A1 (pt)
JP (1) JP5805880B2 (pt)
KR (1) KR101272613B1 (pt)
CN (2) CN110003174A (pt)
AU (1) AU2012319291B2 (pt)
BR (1) BR112014007718B1 (pt)
CA (1) CA2850055C (pt)
CY (1) CY1122758T1 (pt)
DK (1) DK2763981T3 (pt)
ES (1) ES2775197T3 (pt)
HR (1) HRP20200426T1 (pt)
HU (1) HUE048798T2 (pt)
IL (3) IL231911B (pt)
IN (1) IN2014DN03447A (pt)
LT (1) LT2763981T (pt)
MX (1) MX348815B (pt)
PL (1) PL2763981T3 (pt)
PT (1) PT2763981T (pt)
RS (1) RS60118B1 (pt)
RU (1) RU2563630C1 (pt)
SI (1) SI2763981T1 (pt)
WO (1) WO2013051883A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR20140096571A (ko) * 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
CN104513229A (zh) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
RU2720810C2 (ru) 2015-03-20 2020-05-13 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. Соли производного хиназолина и способ их получения
WO2020053816A1 (en) * 2018-09-14 2020-03-19 Hanmi Pharmaceutical Co., Ltd. Crystalline forms of a quinazole compound and its hydrochloride salts
KR101950942B1 (ko) * 2019-01-28 2019-02-22 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
US20210221792A1 (en) * 2020-01-16 2021-07-22 Hanmi Pharm Co., Ltd. Convergent synthesis of poziotinib derivative
US20220064145A1 (en) * 2020-08-28 2022-03-03 Hanmi Science Co., Ltd. Synthesis of poziotinib derivative

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
CN1882570B (zh) * 2003-09-19 2010-12-08 阿斯利康(瑞典)有限公司 喹唑啉衍生物
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
BRPI0619603A2 (pt) * 2005-12-12 2011-10-11 Boehringer Ingelheim Int heterociclos bicìclicos, sais fisiologicamante compatìveis, medicamentos que contêm esses compostos, bem como uso e processos para produção dos heterociclos bicìclicos
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
US8450482B2 (en) * 2009-04-23 2013-05-28 Astrazeneca Ab Process for the preparation of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-([1-(N-methylcarbamoymethyl)piperidin-4-yl]oxy)quinazoline

Also Published As

Publication number Publication date
IN2014DN03447A (pt) 2015-06-26
EP2763981B1 (en) 2020-01-08
CY1122758T1 (el) 2021-03-12
CN103857672A (zh) 2014-06-11
IL231911B (en) 2018-06-28
CA2850055E (en) 2013-04-11
JP2014528444A (ja) 2014-10-27
US20140275534A1 (en) 2014-09-18
CN110003174A (zh) 2019-07-12
CN103857672B (zh) 2018-11-30
KR20130037079A (ko) 2013-04-15
IL259694B (en) 2022-04-01
WO2013051883A2 (en) 2013-04-11
CA2850055C (en) 2016-05-17
BR112014007718B1 (pt) 2022-02-22
DK2763981T3 (da) 2020-03-16
WO2013051883A3 (en) 2013-06-06
EP2763981A4 (en) 2015-02-25
HUE048798T2 (hu) 2020-08-28
PT2763981T (pt) 2020-03-25
PL2763981T3 (pl) 2020-08-10
AU2012319291B2 (en) 2016-03-31
CA2850055A1 (en) 2013-04-11
AU2012319291A1 (en) 2014-05-22
EP3611172A1 (en) 2020-02-19
ES2775197T3 (es) 2020-07-24
IL291738A (en) 2022-05-01
SI2763981T1 (sl) 2020-07-31
JP5805880B2 (ja) 2015-11-10
RS60118B1 (sr) 2020-05-29
HRP20200426T1 (hr) 2020-09-04
EP2763981A2 (en) 2014-08-13
IL231911A0 (en) 2014-05-28
KR101272613B1 (ko) 2013-06-10
LT2763981T (lt) 2020-05-25
RU2563630C1 (ru) 2015-09-20
MX348815B (es) 2017-06-30
IL259694A (en) 2018-07-31
US8859767B2 (en) 2014-10-14
MX2014003959A (es) 2014-05-14

Similar Documents

Publication Publication Date Title
BR112014007718A2 (pt) método para preparar hidrocloreto de 1-(4-(4-(3,4-dicloro-2-fluorofenilamino)-7-metoxiquinazolin-6-iloxi)piperidin-1-il)-prop-2-en-1-ona e intermediários usados no mesmo
BR112014001279A2 (pt) composto, uso do composto, composição farmacêutica, e, método para tratar um indivíduo que sofre com um distùrbio mediado pela tirosina cinase de bruton (btk)
IL231025A (en) 1-pyrazolyl-3 - (4 - ((2-anilinopyrimidine-4-yl) oxy) methylated-1-yl) Oriase for use as kinase inhibitors map 38p
CR20120406A (es) Identificación de mutación lkb1 como un biomarcador predictivo para sensibilidad a inhibidores de tor cinasa
CR20130102A (es) Imidazopiridazinas sustituidas
BR112014004560A2 (pt) compostos e composições como inibidores de c-kit quinase
UA111725C2 (uk) Кристалічний (r)-(e)-2-(4-(2-(5-(1-(3,5-дихлорпіридин-4-іл)етоксі)-1h-індазол-3-іл)вініл)-1h-піразол-1-іл)етанол
BR112012022513A2 (pt) derivados de piperidin-4-il azetidina como inibidores de jak1
BRPI0907382B8 (pt) antagonista de receptor de opioide seletivo capa, seu uso e composição farmacêutica que o compreende
BR112014026952A2 (pt) derivados de aminopirimidina pirazol como moduladores lrrk2
BR112014007622A2 (pt) inibidores de flt3 cinase macrocíclicos
AR088570A1 (es) Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton
CO6592093A2 (es) Polimorfos y solvatos de clorhidrato de 4-(2-((5-metil-1-(2-naftalenil)-1h-pirazol-3-il)oxi9etil)morfolina
CY1119800T1 (el) Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων
EA201171063A1 (ru) Фармацевтические составы олмесартана
GT201200150A (es) Método para el tratamiento de trastornos proliferativos y otras condiciones patológicas mediadas por la actividad de cinasa de brc-abl,c-kit, ddr1, ddr2 o pdgf-r
BR112014011453A2 (pt) n-metil-2-[3-((e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida para o tratamento de leucemia mielógena crônica
CR11601A (es) Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa
BR112014009308A2 (pt) formas de dosagem sólida de 2-amino-3-(4-(2-amino-6-((r)-1-(4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifloroetóxi) pirimidin-4-il)fenil) propanoato de (s)-etila
NZ739521A (en) Pharmaceutical compositions
CO7160116A2 (es) Derivados de pirimidinona como agentes antimalaricos
BR112015013725A2 (pt) cepa de levedura
GB2514285A (en) Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
BR112014024736A2 (pt) antagonista receptor de h3 para uso no tratamento de doença de alzheimer
DOP2012000085A (es) Derivados de 3,5-diciano-4-(1h-indazol-5-il)-2,6-dimetil-1,4-dihidropiridina fluoro-sustituidos y procedimientos de uso de los mismos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/10/2012, OBSERVADAS AS CONDICOES LEGAIS.